Fulgent to Present FID-007 Clinical Data at ASCO 2024

Fulgent Pharma, a subsidiary of Fulgent Genetics, Inc., has announced that it will present Phase 1 clinical data on its leading therapeutic candidate, FID-007, at the American Society for Clinical Oncology (ASCO) Annual Meeting on June 2, 2024, in Chicago, Illinois. FID-007 is being developed to treat head and neck cancer. The presentation, titled "Efficacy from the phase 1 study of FID-007, a novel nanoparticle paclitaxel formulation, in patients with head and neck squamous cell carcinoma," will be part of a poster session from 9:00 a.m. to 12:00 p.m. Central Time on June 2, 2024. The abstract, numbered #6042, will be displayed on Poster Board #345.

FID-007 is composed of paclitaxel encapsulated in a polyethyloxazoline (PEOX) polymer excipient designed to improve pharmacokinetics (PK), biodistribution, and tolerability. The PEOX nanoparticle helps the drug stay in solution until it can enter cancer cells and is engineered to preferentially deliver paclitaxel to tumors through leaky, hyperpermeable vasculature.

Fulgent Pharma started as part of Fulgent LLC in Temple City, California, in 2011. It transitioned into the field of precision medicine and clinical genetic and genomic testing. In 2016, Fulgent LLC was divided into two entities: Fulgent Pharma and Fulgent Genetics, each pursuing distinct objectives. Fulgent Genetics acquired Fulgent Pharma in 2022 to advance personalized cancer genomics and oncology therapeutics. Fulgent Pharma is now focused on developing drug candidates for a wide range of cancers, collaborating with institutions like the University of Southern California, Moffitt Cancer Center, and ANP Technologies.

Fulgent Genetics is a technology-based company with a strong clinical diagnostic business and a therapeutic development division. It provides molecular diagnostic testing services, genetic testing, and anatomic pathology laboratory services. The therapeutic development sector is working on novel nanoencapsulation and targeted therapy platforms to enhance the therapeutic window and pharmacokinetic properties of new and existing cancer treatments. Fulgent Genetics aims to evolve into an integrated precision medicine company.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!